Published in Clin Cancer Res on March 09, 2010
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (2011) 2.00
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Autophagy and cancer therapy. Cancer Biol Ther (2011) 1.32
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21
Targeting cancer metabolism. Clin Cancer Res (2012) 1.21
Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One (2011) 1.19
Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol (2011) 1.16
Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol (2011) 1.09
Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer (2013) 1.07
Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog (2013) 1.07
Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal (2011) 1.04
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget (2013) 1.01
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women. Endocr Relat Cancer (2011) 1.01
LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol (2010) 0.99
The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer (2013) 0.96
AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling. Genes Cancer (2013) 0.94
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
Metformin Use Is Associated With Better Survival of Breast Cancer Patients With Diabetes: A Meta-Analysis. Oncologist (2015) 0.89
Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget (2015) 0.87
Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int (2015) 0.87
Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat (2010) 0.86
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. PLoS One (2015) 0.84
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia (2013) 0.83
Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett (2012) 0.83
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer (2012) 0.83
The use of metformin is associated with decreased lumbar radiculopathy pain. J Pain Res (2013) 0.83
Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis. Oncotarget (2015) 0.83
Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell Int (2014) 0.81
Asymmetric dimethylarginine attenuates serum starvation-induced apoptosis via suppression of the Fas (APO-1/CD95)/JNK (SAPK) pathway. Cell Death Dis (2013) 0.80
Cancer stem cells in breast cancer. Cancers (Basel) (2011) 0.80
Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol (2015) 0.80
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget (2016) 0.80
Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care (2015) 0.79
Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia (2017) 0.78
Protective effect of metformin against cisplatin-induced ototoxicity in an auditory cell line. J Assoc Res Otolaryngol (2013) 0.78
Impaired glucose metabolism treatment and carcinogenesis. Oncol Lett (2015) 0.77
Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. Oncol Rep (2016) 0.77
Development of second generation peptides modulating cellular adiponectin receptor responses. Front Chem (2014) 0.77
Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf (2014) 0.77
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer. Curr Breast Cancer Rep (2011) 0.75
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology (2017) 0.75
Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control (2015) 0.75
Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. J Cancer (2017) 0.75
Metformin targets multiple signaling pathways in cancer. Chin J Cancer (2017) 0.75
Gestational diabetes mellitus may be associated with increased risk of breast cancer. Br J Cancer (2017) 0.75
To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents. Stroke Res Treat (2017) 0.75
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol (2007) 15.30
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Metformin. N Engl J Med (1996) 7.66
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev (2002) 6.43
AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res (2007) 6.36
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
LKB1-dependent signaling pathways. Annu Rev Biochem (2006) 5.91
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene (2008) 5.85
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 2.66
The IGF-1 receptor in cancer biology. Int J Cancer (2003) 2.66
Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol (1994) 2.65
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem (2003) 2.52
5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes (2000) 2.39
Diabetes mellitus and breast cancer. Lancet Oncol (2005) 2.34
Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes (2006) 2.24
Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem (2005) 2.24
Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab (2002) 1.88
Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur J Biochem (1989) 1.88
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 1.72
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat (2008) 1.64
Targeting insulin-like growth factor pathways. Br J Cancer (2006) 1.57
Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol (2008) 1.47
Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene (2006) 1.44
Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem (2002) 1.38
Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology (1998) 1.27
AMPK and Raptor: matching cell growth to energy supply. Mol Cell (2008) 1.27
Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab (1997) 1.04
Regulation of IGF-I receptor signaling in tumor cells. Horm Metab Res (2004) 1.01
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Accuracy and self correction of information received from an internet breast cancer list: content analysis. BMJ (2006) 3.46
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol (2007) 2.19
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol (2010) 2.12
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol (2011) 1.96
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol (2007) 1.92
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg (2009) 1.89
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer (2008) 1.88
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol (2011) 1.79
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Trends for inflammatory breast cancer: is survival improving? Oncologist (2007) 1.70
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg (2006) 1.70
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol (2004) 1.61
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg (2005) 1.61
Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer (2007) 1.54
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol (2004) 1.52
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res (2005) 1.51
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer (2005) 1.50
Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell (2009) 1.48
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila) (2009) 1.47
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol (2008) 1.46
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol (2010) 1.45
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2006) 1.44
Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. J Med Internet Res (2004) 1.39
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer (2007) 1.38
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) (2010) 1.35
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics (2012) 1.33
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther (2009) 1.33
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg (2003) 1.33
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer (2007) 1.32
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol (2010) 1.30
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer (2008) 1.30
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol (2012) 1.29
Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer. Cancer (2008) 1.29
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat (2008) 1.28
cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res (2012) 1.28
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer (2010) 1.28
The impact of pregnancy on breast cancer outcomes in women<or=35 years. Cancer (2009) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26
Instruments to assess the quality of health information on the World Wide Web: what can our patients actually use? Int J Med Inform (2005) 1.21
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther (2010) 1.21
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer (2004) 1.18
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer (2004) 1.18
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell (2011) 1.17
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg (2007) 1.16
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer (2009) 1.16
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res (2012) 1.16
Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer (2004) 1.16
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res (2013) 1.14
A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer (2011) 1.14
Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun (2007) 1.13
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg (2009) 1.13
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer (2011) 1.12
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (2010) 1.11
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg (2012) 1.10
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer (2006) 1.10
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer (2008) 1.10
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg (2012) 1.09
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol (2003) 1.08
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer (2005) 1.08
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys (2008) 1.07
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg (2006) 1.07
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat (2011) 1.06
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg (2011) 1.05
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer (2011) 1.05
Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer (2006) 1.05